The FDA has approved a supplemental New Drug Application to expand the label of bupivacaine liposome injectable suspension (Exparel, Pacira BioSciences) to include administration in adults as an adductor canal block and a sciatic nerve block in the popliteal fossa.
According to the company, this new indication provides additional flexibility in the use of bupivacaine liposome injectable suspension as a regional analgesic for more than 3 million lower extremity procedures annually, further